India Approves Novo Nordisk Wegovy For Fatty Liver Disease

The Central Drugs Standard Control Organisation (CDSCO) has officially authorized the use of Novo Nordisk’s weight-loss drug, Wegovy, for treating metabolic dysfunction-associated steatohepatitis (MASH), commonly referred to as fatty liver disease. This regulatory milestone marks a significant expansion in the therapeutic application of semaglutide in India. The approval allows healthcare providers to prescribe this GLP-1 receptor agonist for patients suffering from advanced liver conditions associated with metabolic syndrome.

Clinical research has highlighted the efficacy of GLP-1 drugs in reducing liver inflammation and fibrosis, providing a non-surgical intervention for patients previously limited by few treatment options. The rising prevalence of lifestyle-related liver conditions in India has created an urgent need for pharmacological solutions that target metabolic pathways directly. Novo Nordisk’s drug has shown promise in reducing fat accumulation in the liver, offering potential relief for patients with advanced disease states who are at risk of progressive complications.

Industry observers note that the approval could boost the local healthcare sector, with firms like Emcure Pharma already experiencing market interest following the announcement. For patients, this introduces a high-profile, evidence-based treatment option, though access will likely depend on prescription guidelines and insurance coverage. As healthcare systems look to combat the growing burden of obesity-related diseases, this development underscores the increasing focus on metabolic medicine in the Indian pharmaceutical landscape.